Retatrutide and gynaecomastia are two topics increasingly appearing together in online discussions, but the clinical reality is more nuanced than many sources suggest. Gynaecomastia — the benign enlargement of glandular breast tissue in males — has distinct causes and treatment pathways that differ significantly from simple chest fat accumulation. Retatrutide is an investigational triple receptor agonist not yet licensed in the UK, and there is currently no clinical evidence that it can treat or reverse true gynaecomastia. This article explains what gynaecomastia is, how retatrutide works, and what NHS-approved options are actually available.

What Is Gynaecomastia and What Causes It?

Gynaecomastia is benign glandular breast tissue enlargement in males caused by a relative imbalance between oestrogen and androgen activity; it differs from pseudogynaecomastia, which is fatty chest tissue accumulation linked to obesity.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males.^[1][2] It is a relatively common condition that can affect males at any age, from newborns and adolescents to older adults. It is important to distinguish true gynaecomastia — which involves actual glandular tissue growth — from pseudogynaecomastia, which is the accumulation of fatty tissue in the chest area, often associated with obesity or excess body weight.

The underlying cause of true gynaecomastia is typically an imbalance between oestrogen and androgen (testosterone) activity in breast tissue. Even though males produce only small amounts of oestrogen, any relative increase in oestrogen effect — or decrease in testosterone — can stimulate breast tissue growth. It is also worth noting that excess adipose (fat) tissue increases the activity of the enzyme aromatase, which converts androgens to oestrogen; this means obesity can contribute to a hormonal environment that promotes glandular tissue growth, not only fat accumulation in the chest.^[1][12] Weight loss may therefore reduce both the fatty component and, to a lesser extent, this hormonal effect — but it does not reliably resolve established glandular gynaecomastia.

Common causes include:

• Hormonal changes during puberty (typically peaking around ages 13–14) or older age^[4]

• Medications, including anabolic steroids, anti-androgens (such as bicalutamide, finasteride, spironolactone), some antipsychotics, cimetidine, certain antidepressants, antiretrovirals, and some antihypertensives

• Medical conditions such as hypogonadism, hyperthyroidism, liver cirrhosis, or chronic kidney disease

• Recreational drug use, including cannabis and alcohol

• Idiopathic causes, where no clear trigger is identified

If you suspect a prescribed medicine may be contributing to gynaecomastia, it is important not to stop taking it without first speaking to your GP or specialist, as doing so may carry its own risks.

In adolescent males, physiological gynaecomastia often resolves spontaneously, typically within 6–24 months.^[12] However, persistent or symptomatic cases — particularly those causing pain, tenderness, or psychological distress — warrant clinical evaluation. Understanding the distinction between true gynaecomastia and pseudogynaecomastia is essential when considering any treatment approach, including newer weight-loss medications.

How Retatrutide Works and What It Is Licensed For

Retatrutide is an unlicensed investigational triple receptor agonist (GLP-1, GIP, glucagon) not approved by the MHRA or EMA; there is no clinical evidence it can treat or reverse gynaecomastia.

Retatrutide is an investigational triple receptor agonist that targets three incretin-related receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple mechanism of action distinguishes it from existing licensed agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GLP-1/GIP receptor agonist). By activating all three pathways, retatrutide is designed to produce significant reductions in body weight and improve metabolic parameters, including blood glucose control.

As of the time of writing, retatrutide is not licensed for use in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) or approved by the European Medicines Agency (EMA). It is not available on prescription in the UK outside of clinical trials. Phase 2 trial data, published in peer-reviewed literature, have shown promising results for weight reduction and glycaemic control in adults with obesity or type 2 diabetes; Phase 3 trials are ongoing and results have not yet been fully published.^[5][8] Patients should be aware that purchasing retatrutide through unofficial online sources is not only unlicensed but carries significant safety risks, as such products have not been assessed for quality, safety, or efficacy by the MHRA.

Critically, there is no clinical evidence or licensed indication to suggest that retatrutide can treat or reverse gynaecomastia. Whilst significant weight loss achieved through any means — including GLP-1-based therapies — may reduce the fatty component of chest enlargement (pseudogynaecomastia), it does not address the glandular tissue that defines true gynaecomastia. The hormonal imbalance driving glandular growth is not corrected by GLP-1, GIP, or glucagon receptor activation. Patients should be cautious about claims circulating online suggesting that weight-loss medications can 'get rid of gyno'; there is no evidence supporting a link between retatrutide and the treatment of gynaecomastia.

NHS Treatment Options for Gynaecomastia

NHS management focuses on treating the underlying cause; off-licence tamoxifen may help recent, painful gynaecomastia, while surgical reduction is available for persistent or fibrotic cases subject to local ICB policy.

The NHS approach to gynaecomastia is guided by identifying and addressing the underlying cause wherever possible. If a medication is identified as the likely trigger, a GP may review whether a suitable alternative can be prescribed — but patients should not stop any prescribed medicine without medical advice. Similarly, treating an underlying medical condition — such as correcting thyroid dysfunction or managing hypogonadism — may lead to resolution of breast tissue changes over time.

For physiological gynaecomastia in adolescents, a watchful waiting approach is often recommended, as the condition frequently resolves without intervention within 6–24 months. Reassurance and monitoring are central to management in this group.

Where gynaecomastia is persistent, symptomatic, or causing significant psychological distress, further options may include:

• Pharmacological treatment: Medications such as tamoxifen (a selective oestrogen receptor modulator) are sometimes used off-licence in the UK for gynaecomastia.^[9][10] Tamoxifen has comparatively better evidence than anastrozole (an aromatase inhibitor) and tends to be most effective for recent, painful gynaecomastia — ideally within approximately the first 12 months, before fibrotic changes occur. Long-standing, fibrotic gynaecomastia is unlikely to respond to medical therapy. These treatments are not routinely commissioned by the NHS for this indication and would typically be initiated by a specialist, such as an endocrinologist. Refer to the BNF and individual Summary of Product Characteristics (SmPC) for current dosing, cautions, and off-label use context.

• Surgical treatment: Surgical reduction (mastectomy or liposuction-assisted techniques) may be considered for longstanding or fibrotic gynaecomastia that has not responded to other measures. Access to NHS-funded surgery varies by local Integrated Care Board (ICB) policy, and patients should discuss eligibility with their GP or specialist.

Typical referral pathways include GP referral to endocrinology where an endocrine cause is suspected, or to breast surgery or plastic surgery for assessment of persistent cases or surgical options. NICE does not currently have a specific guideline dedicated solely to gynaecomastia management, but NICE Clinical Knowledge Summaries (CKS) and guidance on obesity, endocrine conditions, and medicines optimisation inform clinical decision-making. Patients are encouraged to discuss their symptoms openly with their GP rather than seeking unregulated treatments, which may carry unknown risks.

When to Speak to a GP About Gynaecomastia

Speak to a GP promptly if breast enlargement is persistent, painful, or accompanied by nipple discharge or a hard lump, as urgent 2-week-wait referral may be needed to exclude male breast cancer.

Many men and adolescents feel embarrassed about gynaecomastia and may delay seeking medical advice. However, early assessment is important to rule out serious underlying causes and to access appropriate support. You should speak to a GP if you notice:

• Breast tissue enlargement that is persistent, growing, or affecting one or both sides

• Pain or tenderness in the breast area

• Nipple discharge, which always requires prompt evaluation

• Rapid onset of breast enlargement, which may suggest an underlying hormonal or systemic condition

• Symptoms accompanied by unexplained weight loss, fatigue, or testicular changes, which may indicate a more serious cause requiring investigation

Certain features require urgent assessment. In line with NICE guidance on suspected cancer (NICE NG12), you should seek prompt GP review — and may be referred urgently to a breast clinic on a 2-week-wait pathway — if you notice a hard or irregular unilateral breast lump, skin or nipple changes (such as dimpling, tethering, or inversion), blood-stained nipple discharge, or swollen lymph nodes in the armpit. These features can occasionally indicate male breast cancer and must be assessed promptly.

A GP will typically take a thorough medical and medication history, perform a physical examination, and may arrange blood tests to assess hormone levels. These may include testosterone, oestrogen (estradiol), LH, FSH, prolactin, beta-hCG (to help exclude a testicular or other tumour), as well as liver and kidney function and thyroid function tests. Where breast findings are suspicious, referral for triple assessment at a breast clinic (clinical examination, imaging, and biopsy if indicated) is the appropriate pathway rather than GP-arranged mammography alone.^[13] In some cases, testicular ultrasound may also be requested.

It is also important to speak to a GP before using any unlicensed or unregulated medication — including retatrutide obtained through unofficial channels — as these carry significant safety risks. Unlicensed medicines have not been assessed for quality, safety, or efficacy by the MHRA. If you experience a suspected side effect from any medicine, including an unlicensed product, you can report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

If gynaecomastia is causing significant psychological distress, a GP can also refer to appropriate mental health or counselling services. Overall, the most effective and safest path to managing gynaecomastia begins with an honest conversation with a qualified healthcare professional, rather than relying on unverified claims about weight-loss medications or supplements found online.

Frequently Asked Questions